Protara Therapeutics disclosed that the majority of their funds are invested in short-term and high-credit treasury and corporate bonds, and their cash, cash equivalents, and marketable debt securities totaled $102.3 million as of December 31, 2022. They do not believe that the issues faced by Silicon Valley Bank will impact their operations or liquidity, and they reiterate their guidance on cash runway into 2025.